Formulation and Delivery
Naoki Yamada, Dr.
Head of Marketing and Strategy
FUJIFILM Pharmaceuticals U.S.A., Inc.
Cambridge, Massachusetts
Description: Lipid Nanoparticles (LNPs) have been used for diverse applications, including vaccines, liver-targeted protein production, and extrahepatic delivery for in vivo CAR T therapy. The ionizable lipid incorporated into LNPs is a critical determinant of high delivery efficiency and safety. This presentation will show the current challenges and optimal ionizable lipid selection for these applications.
 Beyond classical use liposome for low-molecular-weight cytotoxic agents, we will discuss emerging applications that extend liposome technology, including combination therapies with immune checkpoint inhibitors and the delivery of protein degraders (TPDs) and other synthetic mid-molecular weight compounds. In-house data demonstrating the potential of liposomes for these applications will be presented.